Search Results

You are looking at 11 - 20 of 534 items for :

  • All content x
Clear All

Adams, H. P., Adams, R. J. Jr., Brott, T. és mtsai: Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke

Restricted access

954 959 Toyoda, K., Fujii, K., Fujimi, S. és mtsai: Stroke in patients on maintenance hemodialysis: a 22-year single-center study. Am. J. Kidney Dis., 2005, 45

Restricted access
Acta Physiologica Hungarica
Authors: G. Nyírő, G. Inczédy-Farkas, V. Reményi, A. Gál, Zs Pál, and Mária Molnár

Clopidogrel is an inhibitor of platelet-aggregation used in the prevention of secondary stroke. The molecule is activated by the cytochrome P450 2C19 (CYP2C19) enzyme. The frequent CYP2C19*2 point mutation causes loss of enzyme function, a decreased (heterozygous form) or blocked (homozygous form) formation of the active molecule. Thus, for a patient harboring a mutated allele, clopidogrel does not provide effective protection against stroke. Multiple drugs inhibit the CYP2C19 enzyme and their simultaneous use with clopidogrel is especially hazardous for patients with genetically decreased enzyme activity. Frequency of the CYP2C19*2 is variable in different populations, highest rates were detected in some Asian groups. In our study the CYP2C19 genotype was determined in one Hungarian sample of 354 stroke patients and 221 healthy controls. Frequency of the minor allele was found to be 12.87% (12.85% in stroke patients, 12.89% in healthy controls). The proportion of the homozygous CYP2C19*2 variant causing total loss of gene function was 1.74%, rate of the heterozygous allele causing reduced enzyme activity was 22.26% in the total population. Our results for the allele frequencies of the CYP2C19*2 gene are similar to those found in other Caucasian populations. In conclusion, the homozygous mutation, causing ineffectiveness of clopidogrel is relatively rare. However, the heterozygous form in which interaction of CYP2C19 inhibitors causes further decrease in the genetically impaired enzyme activity is present in every fifth drug-taking patient. Based on our findings, we would like to emphasize that it is important to adjust individually antiplatelet treatment in ischemic stroke patients and to take into consideration genetic factors as well as drugs taken for comorbid conditions.

Restricted access

Asplund, K.: What MONICA told us about stroke. Lancet Neurol., 2005, 4 , 64–68. Asplund K. What MONICA told us about

Restricted access

Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on

Restricted access
Orvosi Hetilap
Authors: Vitalie Văcăraș, Zoltán Zsigmond Major, Emilia Mariș, Kinga Andrea Major, and Anca Dana Buzoianu

–699. 5 Przeklasa-Auth, M., Ovbiagele, B., Yim, C., et al.: Multiple sclerosis with initial stroke-like clinico-radiologic features: case report and literature review. J. Child Neurol., 2010

Restricted access

Fazekas A.: Gondolatok a stroke, avagy gutaütés, avagy szélütés elnevezésekkel kapcsolatban. Agyérbetegségek, 2005, 11 , 12–13. Fazekas A

Restricted access

: 837–847. 3 Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke

Open access

(MRI) may be useful to investigate concomitant cerebral embolisms. Here, we report a case of native mitral valve endocarditis with vascular complications. The unusual presentation with STEMI and concomitant stroke was due to multiple coronary and

Open access

.E. Singer 2001 Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

Restricted access